Shield Therapeutics plc (LON:STX – Get Free Report)’s share price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 7.52 and traded as low as GBX 6.07. Shield Therapeutics shares last traded at GBX 6.27, with a volume of 2,088,825 shares traded.
Shield Therapeutics Stock Performance
The stock has a market cap of £68.45 million, a price-to-earnings ratio of -3.20 and a beta of 1.88. The company has a debt-to-equity ratio of -199.87, a quick ratio of 2.16 and a current ratio of 0.90. The stock’s 50-day simple moving average is GBX 7.47 and its two-hundred day simple moving average is GBX 9.08.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
